Search results
Added:
5 months ago
Source:
Radcliffe CVRM
Patients receiving maintenance haemodialysis have a cardiovascular mortality rate more than 20 times higher than the general population, and many standard preventative therapies have proven ineffective in this high-risk group. The results of a new randomised clinical trial, PISCES, suggest that daily supplementation with fish oil could offer a significant benefit, substantially reducing the rate…
View more
Stephanie L Mick
Job title: Director, Minimally Invasive and Robotic Surgery
Author
Robert Gerber
Job title: Consultant Interventional Cardiologist and Associate Professor
Author
Mirvat Alasnag
Research Area(s) / Expertise:
Author
Expertise
Patrick W Serruys
Job title: Professor of Interventional Medicine
Author
Added:
1 year ago
Source:
European Renal Association
The SELECT Trial has revealed the potential of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in combating kidney function decline among individuals with overweight or obesity and established cardiovascular disease but without diabetes.1Unveiling the results today at the 61st ERA Congress, researchers presented the impressive secondary analysis from the SELECT (Semaglutide…
View more
Link Between NAFLD/NASH and Cardiometabolic Syndrome
Author(s):
Sheila Gato
,
Vanessa García-Fernández
,
Antonio Gil-Gómez
,
et al
Added:
1 year ago
Review Article
Treatment Options and Continuity of Care in MAFLD
Author(s):
Carmen Lara-Romero
,
Manuel Romero-Gómez
Added:
1 year ago
Review Article
Cardiovascular Risk in NAFLD
Author(s):
Paula Luque-Linero
,
Jose M Guerra
Added:
1 year ago
Review Article